#India #Accord BioPharma #UDENYCA #Ahmedabad #Pegfilgrastim

Intas Pharmaceuticals and Accord BioPharma Expand Pegfilgrastim Portfolio

In a significant move, Intas Pharmaceuticals, alongside its global subsidiary Accord BioPharma, has solidified its status as a key player in the global pegfilgrastim market by acquiring UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences, Inc. This strategic acquisition significantly enhances Intas and Accord's already impressive biosimilar portfolio, positioning the company for accelerated growth within the burgeoning global biosimilar sector.

Empowering Global Healthcare

The acquisition of UDENYCA, a biosimilar to Neulasta® (pegfilgrastim), is pivotal as it enables the companies to continue providing solutions that address critical healthcare challenges. Intas and Accord have been formidable contenders in the market, especially in Europe, where Accord led the commercialization of the first biosimilar pegfilgrastim product and introduced an innovative autoinjector. Their leadership has remained resilient despite fierce market competition.

Through this acquisition, Accord BioPharma is set to advance the ongoing commercialization of UDENYCA, aiming to reduce the incidence of febrile neutropenia in non-myeloid malignancy patients undergoing myelosuppressive chemotherapy. UDENYCA is particularly valuable as it offers multiple convenient administration options: a user-friendly autoinjector, an on-body injector, and a prefilled syringe, catering to diverse patient needs and enabling flexibility in treatment.

To date, UDENYCA has treated over 300,000 patients and distributed more than 1.4 million units, illustrating its widespread acceptance and efficacy. This impressive outreach underscores the commitment of Intas and Accord BioPharma to improving patient access to high-quality biosimilars.

Integrating Talent for Continued Growth

The acquisition not only expands Accord's product range but also enhances its operational capability by integrating a wealth of talent from Coherus BioSciences. Essential employees who played critical roles across various functions have joined Accord, ensuring a seamless transition and continuity in supply and services.

Chrys Kokino, the U.S. President of Accord BioPharma, emphasized that the completion of this acquisition represents a transformative phase for the company. “It strengthens our market presence and broadens our capabilities as we strive to innovate and excel in the biosimilar space,” he remarked.

Paul Tredwell, the Executive Vice-President for EMENA of Accord, highlighted that having the Accord Biopharma team fully commercializing UDENYCA® in three formulations reinforces Accord's competitive edge and advances their vision of securing a leading position in the pegfilgrastim market.

Commitment to Quality Healthcare

Binish Chudgar, Chairman and Managing Director of Intas Pharmaceuticals, stated, “This addition symbolizes our unwavering commitment to enhancing patient access to high-quality treatments that address the dynamic needs of both patients and healthcare providers.” The acquisition positions Intas as a global leader in pegfilgrastim, facilitating further expansion within key international markets.

About UDENYCA and Its Indications

UDENYCA® (pegfilgrastim-cbqv) is indicated to:

• - Mitigate the risk of infections like febrile neutropenia in patients with non-myeloid malignancies undergoing treatment with myelosuppressive anti-cancer drugs.
• - Improve survival rates for patients exposed to myelosuppressive doses of radiation associated with Hematopoietic Subsyndrome of Acute Radiation Syndrome.

Important Safety Information

UDENYCA comes with essential safety precautions, including:

• - Contraindications: Those with a known history of serious allergic reactions to pegfilgrastim products should avoid UDENYCA.
• - Adverse Reactions: The most prevalent adverse reactions reported include bone pain and pain in the extremities.

Moving Forward

Intas and Accord BioPharma’s acquisition of UDENYCA sets the stage for a new era in biosimilar therapy, one that promises enhanced patient care and access to life-altering treatments. As both companies merge their capabilities and insights, they are poised to make significant advancements in the biosimilars industry.

For further details, please visit Intas Pharma and Accord BioPharma.